Patent · US Active

Modification of extracorporeal photopherisis technology with porphyrin precursors

US10695371B2 · kind B2 · utility

0Cited by

2References

13Claims

0Family size

Assignee

OSLO UNIVERSITETSSYKEHUS · NO

Inventors

Qian Peng · Oslo, NO
Trond Warloe · Oslo, NO
Jahn M. Nesland · Asker, NO
Eidi Christensen · Trondheim, NO
Odrun Arna Gederaas · Trondheim, NO
Toril Holien · Trondheim, NO

Key dates

Filing date	Apr 24, 2015
Grant date	Jun 30, 2020
Priority date	—
Expiry date	Apr 24, 2035

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to the use of a photoactivatable Porphyrin-Derivative in extracorporeal photophoresis (ECP) treatment, in which a patient's blood or part of it containing sad Porphyrin-derivative is/are exposed to light of a wavelength which activates said photoactivatable Porphyrin-Derivative.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.